A Single-Center, Randomized, Open-label, Single-dose, 3-Sequence, 3-Period Rossover Design to Evaluate the Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants
Latest Information Update: 11 Nov 2024
At a glance
- Drugs SYHA 1813 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Shanghai Runshi Pharmaceutical
Most Recent Events
- 08 Nov 2024 Status changed from not yet recruiting to completed.
- 27 Nov 2023 Status changed from planning to not yet recruiting.
- 04 Nov 2022 New trial record